MicroBlate™ Flex Achieves First-Patient Milestone in New European Lung Tumour Clinical Study
A key milestone has been achieved in the ongoing 'ablate and resect' clinical study of the MicroBlate™ Flex device, currently underway in leading European hospitals — Amsterdam University Medical Centre and Royal Brompton Hospital in London. The first patient has been treated, marking an important step in evaluating the safety and performance of this innovative technology for treating lung tumours.
What’s the Study About?
Patients already scheduled for lung tumour surgery are first treated with the MicroBlate Flex, a soft tissue ablation device developed to destroy cancerous tissue. After ablation, the tumour is removed and carefully analysed, allowing doctors to compare how effective the device is versus imaging scans taken before and after the procedure. This type of deep analysis offers critical insight into how well the device works – something only this kind of study can reveal.
This study follows closely behind our ongoing research and builds a post-market programme, with Intuitive, our partner in surgical robotics. The program uses MicroBlate Flex together with Intuitive’s Ion robotic system to deliver precise, robotically guided lung tumour ablation. Our goal is to gather powerful data to assess MicroBlate Flex as it edges closer to a full commercial release.
You can find out more on the official study details here: ClinicalTrials.gov - NCT06689488
Why This Matters in the Lung Cancer Space
MicroBlate Flex is designed to target soft tissue tumours, with lung tumour ablation being one of its most promising uses. Lung cancer is the most common cancer in men and the second most common in women worldwide. Current treatment options – often surgery, chemo or radiation – can be harsh and invasive, and multiple rounds of treatment are usually needed.
MicroBlate Flex could offer a game-changing alternative. The device provides a more targeted, minimally invasive option to treat both early-stage lung cancer and metastatic tumours in the lung, sparing more of the healthy lung tissue in the process, that would otherwise be damaged when using more evasive forms of treatment.
Craig Gulliford, CEO of Creo Medical, shared his optimism:
“We’re delighted to see the start of an additional clinical study to generate data on MicroBlate Flex, which we believe has the potential to become an invaluable tool for treating early lung cancers or metastatic tumours in the lung, whilst minimising damage to healthy parts of the lung. Our collaboration with Intuitive further strengthens our emerging position at the forefront of minimally invasive lung cancer treatment and highlights the broad potential of MicroBlate Flex as we move toward commercialisation.”
Bottom Line:
This latest study is another bold step forward in our mission to transform lung tumour treatment. As clinical data rolls in, MicroBlate Flex is looking more like a promising option in the future of lung cancer care. With the first patient in the study already having been treated, we look forward to sharing fuller results in due course Read the full RNS article for more information.
